<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00542711</url>
  </required_header>
  <id_info>
    <org_study_id>Curcumol-HMO-CTIL</org_study_id>
    <nct_id>NCT00542711</nct_id>
  </id_info>
  <brief_title>Bio-availability of a New Liquid Tumeric Extract</brief_title>
  <official_title>Liquid Tumeric Extract for Increasing Bio-availability of Curcumin in the Human Body: Pharmacokinetic Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <brief_summary>
    <textblock>
      Curcumin is a commonly-used spice and food coloring. Evidence suggests that curcumin can&#xD;
      suppress tumor initiation, promotion and metastasis in a variety of tumor cell lines. The&#xD;
      current available curcumin has low bioavailability restricting the effect of curcumin in&#xD;
      non-colon cancer. In this study we plan to test a new liquid tumeric/curcumin extract,&#xD;
      Curcumol (patent pending, Israel Patent Application No. 181,121). We predict the&#xD;
      bioavailability of the liquid tumeric/curcumin extract will be better compared to the&#xD;
      currently used curcumin powder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twelve healthy participants enrolled to the study. All volunteers will have pre study&#xD;
      evaluation to confirm healthy state. After enrollment, each participant will be tested twice,&#xD;
      one with the liquid tumeric/curcumin (study drug) and once with the curcumin powder&#xD;
      (control). The days of testing will be on two days, separated by two weeks wash-out period.&#xD;
      The participants will be assigned to randomly receive study drug or control on the 1st day,&#xD;
      with the other regimen administered at the 2nd day. Both study drug and control will be&#xD;
      diluted in 150ml of water. The doe of study drug will be escalated from 30 drops (4&#xD;
      participants), 50 drops (4 participants) and 70 drops (4 participants). Blood sample will be&#xD;
      collected at 0,0.25,0.5,0.75,1,2,3,4,5,6,8h post drug. Quantization of curcumin plasma levels&#xD;
      will be done by the high pressure liquid chormatography method. A biomarker for the potential&#xD;
      effect of curcumin, platelet function pre and post curcumin consumption will be tested.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Technical difficulties&#xD;
  </why_stopped>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liquid tumeric/curcumin extract</intervention_name>
    <description>30 drops (4 participants), 50 drops (4 participants) and 70 drops (4 participants). one dose.</description>
    <other_name>Curcumol (patent pending, Israel Patent Application No. 181,121).</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Complete Healthy&#xD;
&#xD;
          -  Able to attend two full days of study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shoshana Revel-Vilk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>October 10, 2007</study_first_submitted>
  <study_first_submitted_qc>October 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2007</study_first_posted>
  <last_update_submitted>August 19, 2015</last_update_submitted>
  <last_update_submitted_qc>August 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <name_title>Hadassah Medical Organization</name_title>
    <organization>Hadassah Medical Organization</organization>
  </responsible_party>
  <keyword>Curcumin</keyword>
  <keyword>Bioavilability</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

